Earnings History Data for Nurix Therapeutics, Inc. (NRIX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Nurix Therapeutics, Inc.

Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
10-04-2024	PM		NRIX	Nurix Therapeutics	678.00	-0.76	-0.80	0.00	Nurix Therapeutics GAAP EPS of -$0.76 beats by $0.04, revenue of $16.59M misses by $0.5M [4/10/2024 7:03 AM]	15.72	-1.76 (-10.07%)	17.15	-0.33 (-1.89%)	4.22 - 17.51	1,482,199	960,000	21,278
Nurix Therapeutics GAAP EPS of -$0.76 beats by $0.04, revenue of $16.59M misses by $0.5M [4/10/2024 7:03 AM] Nurix gains after extending Sanofi research pact [4/9/2024 2:15 PM]
15-02-2024	PM		NRIX	Nurix Therapeutics, Inc.	422.95	-0.77	-0.51	-0.87	Nurix Therapeutics GAAP EPS of -$0.77 misses by $0.38, revenue of $15.2M misses by $21.34M [2/16/2024 1:41 AM]	9.87	0.02 (0.15%)	9.26	-0.59 (-5.99%)	4.22 - 13.99	730,648	540,000	9,100
Nurix Therapeutics GAAP EPS of -$0.77 misses by $0.38, revenue of $15.2M misses by $21.34M [2/16/2024 1:41 AM]
06-10-2022	AH		NRIX	Nurix Therapeutics	627.00	-0.90	-0.99	0.00	Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M [10/6/2022 4:21 PM]	11.05	-0.77 (-6.51%)	12.16	0.34 (2.88%)	7.52 - 36.24	527,943	370,000	208
Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M [10/6/2022 4:21 PM] Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update [Oct-06-22 04:01PM] Nurix Therapeutics Announces Six Poster Presentations at the Upcoming Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting [Oct-05-22 08:00AM] Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates [Oct-06-22 05:15PM]
07-07-2022	AH		NRIX	Nurix Therapeutics	621.00	-1.01	-1.00	0.00	Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M [7/7/2022 4:17 PM]	17.77	2.30 (14.87%)	15.60	0.13 (0.84%)	7.52 - 37.42	577,900	710,000	1,792
Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M [7/7/2022 4:17 PM] Nurix Therapeutics announces $55M registered direct offering [7/7/2022 5:59 PM] Nurix Therapeutics to raise $40M via registered direct offering [7/8/2022 8:04 AM] Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update [Jul-07-22 04:05PM] Nurix Therapeutics Announces $55 Million Registered Direct Offering [Jul-07-22 05:03PM] Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Tops Revenue Estimates [Jul-07-22 05:25PM] Nurix Therapeutics Announces $40 Million Registered Direct Offering [Jul-08-22 08:00AM]
07-04-2022	AH	4:00 PM ET (Apr 7)	NRIX	Nurix Therapeutics	648.00	-0.95	-0.89	0.00	Nurix Therapeutics Q1 GAAP EPS of -$0.95 misses by $0.09, revenue of $9.6M beats by $0.33M [4/7/2022 4:48 PM]	14.86	1.60 (12.03%)	13.26	0.0 (0.00%)	12.54 - 37.42	420,664	490,000	3,730
Nurix Therapeutics Q1 GAAP EPS of -$0.95 misses by $0.09, revenue of $9.6M beats by $0.33M [4/7/2022 4:48 PM] Nurix higher after announcing pre-clinical data for cancer candidates [4/8/2022 3:19 PM] Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update [Apr-07-22 04:01PM] Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates [Apr-07-22 05:15PM] Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting [Apr-08-22 01:02PM]